A randomized double blind placebo controlled clinical trial of buspirone for treating autism spectrum disorders
Phase 2
- Conditions
- Pervasive developmental disorders.Childhood autism
- Registration Number
- IRCT201307303930N28
- Lead Sponsor
- Shiraz University of Medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Inclusion Criteria: DSM-IV diagnosis of autism spectrum disorders; both genders; aged 4 to 17 years.
Exclusion Criteria
a psychosis; and active substance abuse or dependency.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Abbrant Behavior Checklist- irritability subscale. Timepoint: Every 4 weeks. Method of measurement: Interveiw.
- Secondary Outcome Measures
Name Time Method Adverse effects. Timepoint: every 4 weeks. Method of measurement: checklist.